Theratechnologies (THTX) Competitors $3.39 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.42 +0.03 (+0.86%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock THTX vs. DNA, ATYR, OPT, ORKA, ESPR, ARVN, PRME, IVA, OLMA, and AQSTShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Ginkgo Bioworks (DNA), aTyr Pharma (ATYR), Opthea (OPT), Oruka Therapeutics (ORKA), Esperion Therapeutics (ESPR), Arvinas (ARVN), Prime Medicine (PRME), Inventiva (IVA), Olema Pharmaceuticals (OLMA), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Its Competitors Ginkgo Bioworks aTyr Pharma Opthea Oruka Therapeutics Esperion Therapeutics Arvinas Prime Medicine Inventiva Olema Pharmaceuticals Aquestive Therapeutics Ginkgo Bioworks (NYSE:DNA) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Do institutionals & insiders hold more shares of DNA or THTX? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to DNA or THTX? In the previous week, Theratechnologies had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Theratechnologies and 1 mentions for Ginkgo Bioworks. Theratechnologies' average media sentiment score of 1.91 beat Ginkgo Bioworks' score of 0.61 indicating that Theratechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theratechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher earnings and valuation, DNA or THTX? Theratechnologies has lower revenue, but higher earnings than Ginkgo Bioworks. Theratechnologies is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$227.04M2.94-$547.03M-$5.86-1.92Theratechnologies$85.87M1.82-$8.31M-$0.19-17.84 Do analysts prefer DNA or THTX? Ginkgo Bioworks currently has a consensus target price of $9.00, suggesting a potential downside of 20.13%. Given Ginkgo Bioworks' higher probable upside, equities analysts clearly believe Ginkgo Bioworks is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, DNA or THTX? Ginkgo Bioworks has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Is DNA or THTX more profitable? Theratechnologies has a net margin of -10.85% compared to Ginkgo Bioworks' net margin of -136.56%. Theratechnologies' return on equity of 0.00% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-136.56% -43.25% -22.29% Theratechnologies -10.85%N/A -9.83% SummaryTheratechnologies beats Ginkgo Bioworks on 9 of the 17 factors compared between the two stocks. Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.87M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-17.8420.6375.7726.11Price / Sales1.82442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book-6.169.6212.876.30Net Income-$8.31M-$52.73M$3.29B$271.03M7 Day Performance2.42%0.64%-0.26%-0.15%1 Month Performance4.31%6.31%3.84%6.41%1 Year Performance187.29%18.97%68.35%28.81% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$3.39flatN/A+189.7%$155.87M$85.87M-17.84140Positive NewsHigh Trading VolumeDNAGinkgo Bioworks1.0898 of 5 stars$10.27+2.6%$9.50-7.5%+43.7%$592.59M$227.04M-1.75640Gap DownATYRaTyr Pharma2.4971 of 5 stars$1.01-83.3%$23.25+2,202.0%-45.3%$590.86M$230K-1.2653High Trading VolumeOPTOpthea0.5011 of 5 stars$3.41+7.2%$1.33-60.9%-12.3%$583.10M$30K0.008Positive NewsGap UpHigh Trading VolumeORKAOruka Therapeutics2.6219 of 5 stars$15.26-0.9%$40.33+164.3%-36.0%$576.75MN/A-5.43N/AAnalyst RevisionESPREsperion Therapeutics3.9547 of 5 stars$2.78-2.1%$7.00+151.8%+47.3%$572.61M$332.31M-5.67200News CoveragePositive NewsARVNArvinas3.3097 of 5 stars$7.74flat$19.76+155.3%-68.7%$568.26M$372.80M-7.66420News CoverageAnalyst DowngradeInsider TradeBuyback AnnouncementPRMEPrime Medicine0.4202 of 5 stars$4.01-1.5%N/AN/A$547.72M$2.98M0.00N/ANews CoverageGap DownIVAInventiva3.0461 of 5 stars$5.31-5.3%$14.83+179.3%+153.2%$536.67M$9.95M0.00100Gap UpOLMAOlema Pharmaceuticals2.7072 of 5 stars$8.00+3.0%$24.00+200.0%-33.8%$533.29MN/A-4.0470AQSTAquestive Therapeutics1.9433 of 5 stars$5.14+1.8%$10.29+100.1%+7.5%$503.61M$44.13M-7.34160 Related Companies and Tools Related Companies DNA Competitors ATYR Competitors OPT Competitors ORKA Competitors ESPR Competitors ARVN Competitors PRME Competitors IVA Competitors OLMA Competitors AQST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THTX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THTX Stock Alerts